A 39-amino-acid peptide and the first triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. In Phase II trials, it produced up to 24.2% body weight loss at 48 weeks — the highest weight loss ever achieved by a drug in clinical trials. Currently in Phase III development by Eli Lilly.
Retatrutide (LY3437943) is a 39-amino-acid peptide being developed by Eli Lilly as the world's first triple incretin agonist — a single molecule that simultaneously activates GLP-1, GIP, and glucagon receptors. If semaglutide was the first generation and tirzepatide the second, retatrutide represents the third generation of incretin-based obesity therapeutics, adding an entirely new metabolic lever that its predecessors lack.
In the Phase II trial published in the New England Journal of Medicine in 2023 (Jastreboff et al.), the highest dose of retatrutide (12 mg weekly) produced 24.2% mean body weight loss at 48 weeks — the largest reduction ever achieved by any drug in a controlled clinical trial. To put that in context: semaglutide (Wegovy) achieves approximately 15-17% weight loss, tirzepatide (Zepbound) achieves 20-22%, and bariatric surgery typically produces 25-30%. Retatrutide is closing the gap between pharmaceutical and surgical outcomes.
Perhaps more striking than the mean was the distribution: 71% of participants on the highest dose lost more than 15% of their body weight, and a significant proportion exceeded 25%. The weight loss curve at 48 weeks had not yet plateaued, suggesting that longer treatment durations could produce even greater results. Eli Lilly's Phase III program — called TRIUMPH — is now underway, with multiple large-scale trials expected to report results in 2026-2027.
What makes retatrutide conceptually important beyond its weight loss numbers is the glucagon receptor component. Previous incretin therapies reduce caloric intake (by suppressing appetite and slowing gastric emptying) and improve metabolic efficiency (through insulin sensitization). Retatrutide adds a third dimension: it increases energy expenditure — telling the body to burn more calories, primarily through hepatic lipid oxidation and thermogenesis. This means retatrutide attacks the energy balance equation from both sides: fewer calories in and more calories out.
Retatrutide's breakthrough is the addition of glucagon receptor (GCGR) agonism to the GLP-1/GIP dual mechanism pioneered by tirzepatide. Understanding why this matters requires understanding what each of the three receptors contributes — and why the combination is more than the sum of its parts.
The GLP-1 receptor component works identically to semaglutide: it suppresses appetite through hypothalamic POMC/CART neuron activation, enhances glucose-dependent insulin secretion, suppresses glucagon from pancreatic alpha cells, and delays gastric emptying. This is the best-characterized pathway and accounts for the majority of the appetite-reducing effect. See our semaglutide mechanism guide for the full biochemistry.
The GIP receptor component mirrors tirzepatide's GIP pathway: it enhances insulin sensitivity in adipose tissue, promotes healthier fat storage patterns, and may protect against bone loss during rapid weight loss. The GIP signal also appears to amplify GLP-1's glucose-lowering effect, contributing to the impressive HbA1c reductions seen in the Phase II diabetes cohort.
This is retatrutide's unique contribution. Glucagon — traditionally viewed as a counter-regulatory hormone that raises blood sugar during fasting — has powerful metabolic effects beyond glucose homeostasis. GCGR activation stimulates hepatic lipid oxidation (the liver burns stored fat for fuel), increases thermogenesis (the body generates more heat from metabolic activity), and promotes amino acid metabolism. The net effect is an increase in resting energy expenditure — the body burns more calories even at rest.
The historical concern with glucagon agonism has always been hyperglycemia: if you stimulate the liver to release more glucose, you risk dangerous blood sugar spikes. Retatrutide elegantly solves this problem through its simultaneous GLP-1 activation. The GLP-1-mediated insulin secretion and glucagon suppression from pancreatic alpha cells counterbalances the hepatic glucose output driven by GCGR activation. The result is the metabolic benefits of glucagon (energy expenditure, fat oxidation) without the diabetogenic risk. Phase II data confirmed this: patients with Type 2 diabetes on retatrutide showed improved glycemic control, not worsened control.
What makes the triple agonist approach so effective is that each receptor addresses a different component of the energy balance equation. GLP-1 reduces caloric intake (appetite suppression). GIP improves how the body handles nutrients (metabolic efficiency). Glucagon increases caloric expenditure (thermogenesis and fat oxidation). Previous generations of obesity drugs only addressed one or two of these dimensions. Retatrutide addresses all three simultaneously, which likely explains why its weight loss results exceed even high-dose tirzepatide.
| Pathway | Effect | Significance |
|---|---|---|
| GLP-1R agonism | Appetite suppression, insulin secretion, gastric slowing | Same mechanism as semaglutide component |
| GIPR agonism | Enhanced fat metabolism, insulin sensitivity | Same mechanism as tirzepatide GIP component |
| GCGR agonism | Hepatic lipid oxidation, thermogenesis, energy expenditure | NEW: Increases calories burned rather than just reducing calories consumed |
| Glucagon-GLP-1 balance | GLP-1 counteracts glucagon's hyperglycemic effect | Allows metabolic benefits of glucagon without dangerous blood sugar spikes |
| Synergistic weight loss | Three pathways produce greater weight loss than any two combined | 24% vs 22.5% (tirzepatide) vs 17% (semaglutide) |
Retatrutide's clinical evidence is still early-stage compared to semaglutide or tirzepatide, but the Phase II results were exceptional enough to generate enormous scientific and commercial interest. The TRIUMPH Phase III program is the largest and most watched obesity drug trial currently running.
The pivotal Phase II trial enrolled 338 adults with obesity (BMI ≥30) or overweight with comorbidities, randomizing them to placebo or one of four retatrutide doses (1, 4, 8, or 12 mg weekly) for 48 weeks. The results were dose-dependent and striking at every level. At the 12 mg dose, mean weight loss was 24.2%, with 71% of participants losing ≥15% and a meaningful proportion exceeding 25%. Even the moderate 8 mg dose produced 22.8% weight loss. The weight loss trajectory had not plateaued at 48 weeks, strongly suggesting that a 72-week trial (the standard duration for Phase III obesity trials) could show even greater reductions.
A sub-analysis of the Phase II data examined body composition changes using DXA (dual-energy X-ray absorptiometry). Approximately 18% of total body fat mass was lost at the highest dose. Notably, lean mass preservation appeared favorable compared to historical data from GLP-1-only agents — potentially because the glucagon-mediated increase in energy expenditure preferentially drives fat oxidation rather than protein catabolism. This is a critical finding if confirmed in Phase III, as lean mass loss has been a significant concern with semaglutide and tirzepatide.
Perhaps the most clinically exciting secondary finding was the dramatic reduction in liver fat content. In the sub-study using MRI-PDFF (proton density fat fraction), retatrutide produced significant reductions in hepatic steatosis — the accumulation of fat in the liver that drives metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) and its more severe form, NASH. Eli Lilly is evaluating retatrutide as a potential treatment for MASLD/NASH, which currently has very limited approved treatment options and affects an estimated 30% of the global adult population.
Eli Lilly's TRIUMPH program includes multiple large Phase III trials evaluating retatrutide for obesity and Type 2 diabetes. These trials are expected to enroll thousands of participants across multiple countries, with results anticipated in 2026-2027. If the Phase III data confirms the Phase II results, retatrutide could receive FDA approval as early as late 2027 — potentially becoming the most effective approved obesity medication in history.
| Trial | Design | Key Results | Level |
|---|---|---|---|
| Phase II (NEJM 2023) | RCT, n=338, 48 weeks, 4 dose levels | 24.2% mean weight loss at 12 mg; 71% lost ≥15%; not plateaued at 48 weeks | Level I-II |
| Body composition | Phase II DXA sub-analysis | ~18% fat mass loss with favorable lean mass preservation vs GLP-1 agents | Level II |
| MASLD/NASH | Phase II MRI-PDFF sub-study | Significant liver fat reduction; potential MASLD/NASH application | Level II |
| TRIUMPH Phase III | Multiple large-scale RCTs, obesity + T2D | Ongoing; results expected 2026-2027; potential FDA approval 2027-2028 | Pending |
Retatrutide's safety profile from Phase II data is broadly similar to other incretin-based therapies, with gastrointestinal side effects being the most common. However, the glucagon receptor component introduces some unique monitoring considerations.
Nausea occurred in 25-31% of participants (dose-dependent), along with diarrhea and vomiting — rates comparable to tirzepatide and somewhat lower than semaglutide. The gradual dose escalation schedule (starting at low doses and increasing every 4 weeks) helps mitigate GI symptoms, and most participants found them manageable. Discontinuation rates due to GI side effects were in the 4-7% range, similar to other incretins.
A mean heart rate increase of 2-4 beats per minute was observed in the Phase II trial. Small heart rate increases are a known class effect of GLP-1 agonists, but the glucagon component could theoretically amplify this effect through its thermogenic activity. This is being closely monitored in Phase III. For context, semaglutide and tirzepatide also produce small heart rate increases of 1-3 bpm in clinical trials.
Some participants showed elevations in ALT (alanine aminotransferase), a liver enzyme. This finding requires careful interpretation: in the context of dramatic liver fat reduction (which retatrutide clearly produces), transient ALT elevations may actually reflect beneficial hepatic remodeling — the release of enzymes as fatty liver tissue is broken down and replaced. This pattern is seen with other MASLD/NASH treatments. However, the possibility of hepatotoxicity cannot be excluded from Phase II data alone, and liver function monitoring will be a key component of the Phase III safety assessment.
Same boxed warning as all GLP-1 receptor agonists: rodent studies showed dose-dependent thyroid C-cell tumors. Contraindicated in patients with MTC or MEN2 history. No confirmed increase in human thyroid cancer risk from the GLP-1 agonist class to date.
One potential advantage of retatrutide over GLP-1-only agents is better lean mass preservation during weight loss. The glucagon receptor component drives energy expenditure primarily through lipid oxidation (fat burning) and thermogenesis rather than protein catabolism. Phase II DXA data supports this, but confirmation in larger Phase III cohorts with longer follow-up is needed. If confirmed, this would address one of the most significant clinical concerns with current obesity medications.
Retatrutide is not approved anywhere in the world and is only legally available through clinical trial enrollment. Despite this, grey-market vendors have sold products labeled as retatrutide — with alarming quality results. Independent testing by the platform Finnrick gave grey-market retatrutide samples a failing E rating across 37 samples tested between late 2024 and early 2026, with at least one counterfeit detection. This underscores the risk of obtaining unapproved investigational drugs from unregulated sources. Anyone interested in retatrutide should consider clinical trial enrollment through ClinicalTrials.gov.
Retatrutide is an investigational drug with no regulatory approvals anywhere in the world. It is available only through Eli Lilly's TRIUMPH clinical trial program.
| Jurisdiction | Status |
|---|---|
| FDA | Not approved. Phase III ongoing (TRIUMPH program). Potential NDA submission late 2027, approval 2027-2028 if Phase III results are positive. |
| Eli Lilly | Sole developer. Internal designation LY3437943. Retatrutide is the INN (International Nonproprietary Name). |
| Grey market | Products labeled "retatrutide" sold by research peptide vendors have shown extremely poor quality in independent testing (Finnrick E-rating across 37 samples). Counterfeit detections documented. Not recommended from any unregulated source. |
Retatrutide's position in the obesity drug landscape is best understood by comparing it directly with its predecessors. Each generation added a receptor target and achieved incrementally greater weight loss.
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor targets | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Mean weight loss | 15-17% (68 weeks) | 20-22% (72 weeks) | 24.2% (48 weeks, not plateaued) |
| Key addition | Appetite suppression | + Metabolic efficiency | + Energy expenditure |
| Lean mass preservation | Concern (25-40% of loss is lean) | Possibly better than GLP-1 only | Favorable early data (lipid oxidation driven) |
| Liver fat reduction | Modest | Moderate | Significant (MASLD/NASH potential) |
| CV outcomes data | SELECT trial: 20% MACE reduction | Ongoing (SURPASS-CVOT) | Not yet studied |
| Approval status | FDA approved (2017/2021) | FDA approved (2022/2023) | Phase III (potential 2027-2028) |
| Developer | Novo Nordisk | Eli Lilly | Eli Lilly |
The comparison highlights an important nuance: while retatrutide's weight loss numbers are the highest, its evidence base is still Phase II. Semaglutide has the deepest evidence (30,000+ patients across multiple Phase III programs plus real-world data from millions of prescriptions), and tirzepatide has large Phase III data. Retatrutide's Phase II results are exceptional but unconfirmed at Phase III scale. The TRIUMPH results will determine whether the promise translates into a regulatory-grade evidence base.